Open innovation

Our open innovation strategy is designed to promote change beyond GSK by sharing expertise, resources, intellectual property and know-how with external researchers and the scientific community.

Our previous focus was on diseases of the developing world, such as malaria, tuberculosis and parasitic infections and, we are now adapting open innovation models to apply to other areas of great medical need and scientific challenge including infectious, autoimmune disease, immuno-oncology and rare diseases.